Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted, extracellular space Secreted, extracellular space, extracellular matrix Note=Localizes to the lamina propria underneath the olfactory epithelium. |
Domain |
PF12662 Complement Clr-like EGF-like PF07645 Calcium-binding EGF domain |
Function |
Binds EGFR, the EGF receptor, inducing EGFR autophosphorylation and the activation of downstream signaling pathways. May play a role in cell adhesion and migration. May function as a negative regulator of chondrocyte differentiation. In the olfactory epithelium, it may regulate glial cell migration, differentiation and the ability of glial cells to support neuronal neurite outgrowth. |
Biological Process |
GO:0001501 skeletal system development GO:0001654 eye development GO:0002062 chondrocyte differentiation GO:0007173 epidermal growth factor receptor signaling pathway GO:0007423 sensory organ development GO:0007601 visual perception GO:0009791 post-embryonic development GO:0009886 post-embryonic animal morphogenesis GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0032330 regulation of chondrocyte differentiation GO:0032331 negative regulation of chondrocyte differentiation GO:0038127 ERBB signaling pathway GO:0043010 camera-type eye development GO:0048048 embryonic eye morphogenesis GO:0048050 post-embryonic eye morphogenesis GO:0048562 embryonic organ morphogenesis GO:0048563 post-embryonic animal organ morphogenesis GO:0048568 embryonic organ development GO:0048569 post-embryonic animal organ development GO:0048592 eye morphogenesis GO:0050953 sensory perception of light stimulus GO:0051216 cartilage development GO:0061035 regulation of cartilage development GO:0061037 negative regulation of cartilage development GO:0061448 connective tissue development GO:0090596 sensory organ morphogenesis |
Molecular Function |
GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0005006 epidermal growth factor-activated receptor activity GO:0005154 epidermal growth factor receptor binding GO:0008083 growth factor activity GO:0019199 transmembrane receptor protein kinase activity GO:0070851 growth factor receptor binding |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix |
KEGG | - |
Reactome |
R-HSA-1566948: Elastic fibre formation R-HSA-1474244: Extracellular matrix organization R-HSA-2129379: Molecules associated with elastic fibres |
Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between EFEMP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of EFEMP1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of EFEMP1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of EFEMP1 in various data sets.
|
Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EFEMP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EFEMP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EFEMP1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EFEMP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of EFEMP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between EFEMP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | EFEMP1 |
Name | EGF containing fibulin-like extracellular matrix protein 1 |
Aliases | S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ...... |
Chromosomal Location | 2p16 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting EFEMP1 collected from DrugBank database. |
There is no record. |